[ logo.jpg]BioAlliance Pharma SA (Paris:BIO) a specialty pharmaceutical company focused on the treatment of opportunistic infections, in cancer and HIV, today announced the preliminary positive results for its US pivotal Phase III clinical trial wit
Discuss Add this link to...Bury Add to:
| Bookmarks
Comments